The U.S. Food and Drug Administration is actively steering drug developers away from traditional animal studies and toward human-biology-based testing methods for monoclonal antibody programs. The ...

A growing body of research has examined the IRA’s implications for pharmaceutical innovation. Much of this literature has focused on the potential impact on the number of new drug launches, 5, 6 but ...

Drug discovery has traditionally been a reductive process—narrowing down, filtering out, and optimizing within established constraints. Generative AI turns that on its head. It is an expansive force, ...

Scientists at the University of Cambridge have developed a new way to alter complex drug molecules using light rather than ...

As Congress debates renewing the Act for ALS, it must prepare for the coming era of precision ALS medicine by prioritizing ...

Find out how self-driving labs utilise data-driven approaches to enhance drug discovery efficiency and innovation.

Funding and clinical trial-based barriers must be addressed to ensure success on the path to developing a DMT for Parkinson’s.

Cambridge scientists have discovered a light-powered chemical reaction that lets researchers modify complex drug molecules at the final stages of development. Unlike traditional methods that rely on ...